Sun Pharma Adv. Res
Ticker >

Sun Pharma Adv. Res share price

Sun Pharma Advanced Research Company Ltd.

NSE: SPARC BSE: 532872 SECTOR: Business Support  101k   204   22

228.74
+4.20 (1.87%)
NSE: 06 Sep 12:34 PM

Price Summary

Today's High

₹ 232.27

Today's Low

₹ 225.01

52 Week High

₹ 472.8

52 Week Low

₹ 196.1

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 7423.11 Cr.

Enterprise Value

₹ 7315.04 Cr.

No. of Shares

32.45 Cr.

P/E

0

P/B

264.96

Face Value

₹ 1

Div. Yield

0 %

Book Value (TTM)

₹  0.86

CASH

₹ 155.06 Cr.

DEBT

₹ 47 Cr.

Promoter Holding

65.67 %

EPS (TTM)

₹  -12.01

Sales Growth

-68.36%

ROE

-121.73 %

ROCE

-112.88%

Profit Growth

-74.36 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-68.36%
3 Year-33.16%
5 Year-16.21%

Profit Growth

1 Year-74.36%
3 Year-182.81%
5 Year-192.27%

ROE%

1 Year-121.73%
3 Year-88.49%
5 Year-98.11%

ROCE %

1 Year-112.88%
3 Year-135.97%
5 Year-168.19%

Debt/Equity

0.3764

Price to Cash Flow

-17.29

Interest Cover Ratio

-233.4763

CFO/PAT (5 Yr. Avg.)

0

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2024 65.67 2.78
Mar 2024 65.67 2.78
Dec 2023 65.67 2.78
Sep 2023 65.67 2.78
Jun 2023 65.67 2.78
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has a high promoter holding of 65.67%.

 Limitations

  • The company has shown a poor profit growth of -182.810168104835% for the Past 3 years.
  • The company has shown a poor revenue growth of -33.1571013347336% for the Past 3 years.
  • Company has a poor ROE of -88.4851666666667% over the past 3 years.
  • Company has a poor ROCE of -135.967139957342% over the past 3 years
  • Company has low Interest coverage ratio of -233.4763.
  • Company has contingent liabilities of 83.5684 Cr.
  • Company has negative cash flow from operations of -429.4265.
  • The company has a low EBITDA margin of -243.43169369344% over the past 5 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024
Net Sales 23.95 21.18 13.86 16.56 16.81
Total Expenditure 126.13 112.65 116.48 124.08 111.93
Operating Profit -102.18 -91.47 -102.62 -107.52 -95.12
Other Income 10.19 8.49 6.39 4.4 1.56
Interest 0.26 0.26 0.26 0.88 0.52
Depreciation 3.1 3.18 3.16 2.69 2.76
Exceptional Items 0 0 0 0 0
Profit Before Tax -95.35 -86.42 -99.65 -106.69 -96.84
Tax 0 0 0 0 0
Profit After Tax -95.35 -86.42 -99.65 -106.69 -96.84
Adjusted EPS (Rs) -2.94 -2.66 -3.07 -3.29 -2.98

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 76.81 252.96 137.25 238.78 75.55
Total Expenditure 386.83 387.93 324 452.84 479.34
Operating Profit -310.01 -134.98 -186.75 -214.06 -403.79
Other Income 9.76 5.41 6.84 10.88 29.47
Interest 2.67 10.65 13.33 7.63 1.66
Depreciation 9.48 10.92 10.16 11.77 12.13
Exceptional Items 0 0 0 0 0
Profit Before Tax -312.4 -151.14 -203.4 -222.58 -388.11
Tax 0 0 0 0 0
Net Profit -312.4 -151.14 -203.4 -222.58 -388.11
Adjusted EPS (Rs.) -11.92 -5.77 -7.48 -6.86 -11.96

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 26.21 26.21 27.19 32.45 32.45
Total Reserves -44.84 -194.46 4.04 480.32 92.4
Borrowings 6.38 112.5 0 0 0
Other N/C liabilities 49.47 52.09 77.43 138.41 117.59
Current liabilities 235.36 233.35 171.43 178.95 243.89
Total Liabilities 272.56 229.69 280.08 830.13 486.33
Assets
Net Block 103.86 90.56 91.87 105.75 102.65
Capital WIP 3.57 5.23 3.72 1.87 1.27
Intangible WIP 28.49 0 22.65 25.13 42.53
Investments 0 0 0 0 0.42
Loans & Advances 69.24 70.64 67.83 64.8 67.67
Other N/C Assets 0.2 3.46 22.87 177.61 25.4
Current Assets 67.19 59.8 71.15 454.96 246.41
Total Assets 272.56 229.69 280.08 830.13 486.33
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations -312.4 -151.14 -203.4 -222.58 -388.11
Adjustment 9.44 48.75 16.67 6.99 -11.33
Changes in Assets & Liabilities 102.02 -47.88 -26.05 141.11 -25.88
Tax Paid -9.86 -1.63 4.54 5.37 -4.11
Operating Cash Flow -210.81 -151.9 -208.23 -69.12 -429.43
Investing Cash Flow 155.35 1.56 -29.17 -548.28 391.11
Financing Cash Flow 55.46 159.28 229.32 616.76 42.8
Net Cash Flow 0 8.95 -8.08 -0.64 4.48

Corporate Actions

Investors Details

PARTICULARS Jun 2023% Sep 2023% Dec 2023% Mar 2024% Jun 2024%
promoters 65.67 65.67 65.67 65.67 65.67
aalok dilip shanghvi 0.11 0.11 0.11 0.11 0.11
aditya medisales limited 1.51 1.51 1.51 1.51 1.51
dilip shantilal shanghvi 19.05 19.05 19.05 19.05 19.05
kumud s. shanghvi 0.01 0.01 0.01 0.01 0.01
raksha s.valia 1.28 1.28 1.28 1.28 1.28
shanghvi family & friends... 0.05 0.05 0.05 0.05 0.05
shanghvi finance private ... 42.28 42.28 42.28 42.28 42.28
sudhir valia 0.57 0.57 0.57 0.57 0.57
unimed investments limite... 0.39 0.39 0.39 0.39 0.39
vibha dilip shanghvi 0.33 0.33 0.33 0.33 0.33
vidhi dilip shanghvi 0.11 0.11 0.11 0.11 0.11
PARTICULARS Jun 2023% Sep 2023% Dec 2023% Mar 2024% Jun 2024%
investors 34.33 34.33 34.33 34.33 34.33
enam securities private l... 1.04 1.04 1.04 1.04 1.04
jhunjhunwala rekha rakesh... 1.94 1.94 1.94 1.94 1.94
lakshdeep investments & f... 1.57 1.57 1.57 1.58 1.86
paresh mohanlal parekh 1.12 1.12 1.12 1.12 1.12
sun pharmaceutical indust... 3.18 3.18 3.18 3.18 3.18
vijay mohanlal parekh 1.13 1.13 1.13 1.13 1.13

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Sun Pharma Advanced Research Company informs about outcome of board meeting5 Aug 2024, 5:25PM Sun Pharma Adv. Res - Quaterly Results5 Aug 2024, 2:24PM Sun Pharma Adv. Res - Quaterly Results5 Aug 2024, 2:24PM Sun Pharma Adv. Res - Quaterly Results5 Aug 2024, 2:24PM Sun Pharma Adv. Res - Quaterly Results24 May 2024, 8:26PM Sun Pharma Adv. Res - Quaterly Results24 May 2024, 8:26PM Sun Pharma Advanced Research Company informs about compliance certificate10 Apr 2024, 4:06PM Sun Pharma Advanced Research Company informs about press release10 Apr 2024, 9:59AM Sun Pharma Advanced Research Company informs about loss of share certificates7 Mar 2024, 1:15PM Sun Pharma Adv. Res - Quaterly Results5 Feb 2024, 1:49PM Sun Pharma Adv. Res - Quaterly Results5 Feb 2024, 1:49PM Sun Pharma Adv. Res - Quaterly Results5 Feb 2024, 1:49PM Sun Pharma Advanced Research Company informs about clarification on price movement4 Jan 2024, 4:55PM Sun Pharma Advanced Research Company informs about statement on deviation or variation6 Nov 2023, 5:14PM Sun Pharma Adv. Res - Quaterly Results6 Nov 2023, 3:22PM Sun Pharma Adv. Res - Quaterly Results6 Nov 2023, 3:22PM Sun Pharma Adv. Res - Quaterly Results6 Nov 2023, 3:22PM SPARC enters into agreement for SCD-153 with JHU and IOCB2 Nov 2023, 9:52AM Sun Pharma Advanced Research Company informs about press release30 Oct 2023, 9:58AM Sun Pharma Advanced Research Company informs about press release19 Oct 2023, 12:42PM Sun Pharma Advanced Research Company informs about loss of share certificates10 Oct 2023, 5:17PM Sun Pharma Advanced Research Company informs about details of loss of certificate9 Oct 2023, 5:08PM SPARC incorporates wholly owned subsidiary in Delaware26 Sep 2023, 2:05PM Sun Pharma Advanced Research Company informs about loss of share certificates22 Sep 2023, 12:54PM Sun Pharma Adv. Res - Quaterly Results7 Aug 2023, 3:15PM Sun Pharma Adv. Res - Quaterly Results7 Aug 2023, 3:15PM Sun Pharma Adv. Res - Quaterly Results7 Aug 2023, 3:15PM Sun Pharma Advanced Research Company informs about board meeting 29 Jul 2023, 2:25PM Sun Pharma Adv. Res - Quaterly Results22 May 2023, 1:39PM Sun Pharma Adv. Res - Quaterly Results22 May 2023, 1:39PM Sun Pharma Adv. Res - Quaterly Results22 May 2023, 1:39PM Sun Pharma Advanced Research Company informs about details of loss of certificate28 Apr 2023, 1:00PM Sun Pharma Advanced Research Company informs about loss of share certificates18 Apr 2023, 1:14PM Sun Pharma Advanced Research Company informs about closure of trading window30 Mar 2023, 11:17AM Sun Pharma Advanced Research Company informs about IT security incident27 Mar 2023, 9:26AM Sun Pharma Advanced Research Company informs about issuance of duplicate share certificate24 Feb 2023, 4:50PM Sun Pharma Advanced Research Company informs about details of loss of certificate18 Feb 2023, 11:47AM Sun Pharma Adv. Res - Quaterly Results13 Feb 2023, 2:28PM Sun Pharma Adv. Res - Quaterly Results13 Feb 2023, 2:28PM Sun Pharma Adv. Res - Quaterly Results13 Feb 2023, 2:28PM Sun Pharma Advanced Research Company informs about disclosure 11 Jan 2023, 12:42PM Sun Pharma Advanced Research Company informs about closure of trading window23 Dec 2022, 5:15PM Sun Pharma Advanced Research Company informs about issuance of duplicate share certificate5 Dec 2022, 3:52PM SPARC, Sun Pharma get nod for SEZABY from USFDA18 Nov 2022, 11:50AM Sun Pharma Advanced Research Company informs about press release18 Nov 2022, 9:52AM Sun Pharma Advanced Research Company informs about press release9 Nov 2022, 3:57PM SPARC, Sun Pharmaceutical ink licensing agreement9 Nov 2022, 3:00PM Sun Pharma Advanced Research Company informs about no deviation or variation statement 7 Nov 2022, 5:14PM Sun Pharma Adv. Res - Quaterly Results7 Nov 2022, 3:20PM Sun Pharma Adv. Res - Quaterly Results7 Nov 2022, 3:20PM

Sun Pharma Adv. Res Stock Price Analysis and Quick Research Report. Is Sun Pharma Adv. Res an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Sun Pharma Adv. Res stock price today is Rs 229.27. Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Sun Pharma Adv. Res . 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Sun Pharma Adv. Res has a PE ratio of -19.0972395755243 which is low and comparatively undervalued .

  • Share Price: - The current share price of Sun Pharma Adv. Res is Rs 229.27. One can use valuation calculators of ticker to know if Sun Pharma Adv. Res share price is undervalued or overvalued.

  • Return on Assets (ROA): - Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Sun Pharma Adv. Res has ROA of -58.962 % which is a bad sign for future performance. (higher values are always desirable)

  • Current ratio: - The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Sun Pharma Adv. Res has a Current ratio of 1.0103 .

  • Return on equity: - ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Sun Pharma Adv. Res has a ROE of -121.7332 % .(higher is better)

  • Debt to equity ratio: - It is a good metric to check out the capital structure along with its performance. Sun Pharma Adv. Res has a Debt to Equity ratio of 0.3764 which means that the company has low proportion of debt in its capital.

  • Sales growth: - Sun Pharma Adv. Res has reported revenue growth of -68.362 % which is poor in relation to its growth and performance. 

  • Operating Margin: - This will tell you about the operational efficiency of the company. The operating margin of Sun Pharma Adv. Res for the current financial year is -534.502742063371 %.

  • Dividend Yield: - It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Sun Pharma Adv. Res is Rs 0 and the yield is 0 %.

  • Earnings Per Share: - It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Sun Pharma Adv. Res is Rs -12.0054 . The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Sun Pharma Adv. Res in Ticker for free. Also, one can get the intrinsic value of Sun Pharma Adv. Res by using Valuation Calculators, which are available with a Finology ONE subscription. 

Last Updated on:
Brief about Sun Pharma Adv. Res

Sun Pharma Advanced Research Company Ltd. Financials: Check Share price, Balance Sheet, Annual report and Quarterly Results for company analysis

Welcome to the Sun Pharma Advanced Research Company Ltd. stock analysis page, designed to provide long-term stock investors with in-depth analysis of the company's performance. As a leading pharmaceutical research and development company, Sun Pharma Advanced Research Company Ltd. has established itself as a dynamic organization dedicated to innovation and growth. In this comprehensive stock analysis, we will delve into various critical aspects of the company's financial performance and offer valuable insights for potential investors.

Sun Pharma Advanced Research Company Ltd. Share Price:

Sun Pharma Advanced Research Company Ltd.'s share price is a critical factor governing the company's long-term growth potential. Analyzing the movement of the company's share price over time and comparing its performance with industry peers is essential for long-term investors seeking potential investment opportunities. By utilizing our pre-built screening tools, investors can quickly analyze Sun Pharma Advanced Research Company Ltd.'s share price trends and make informed decisions about potential long-term investment opportunities. A stock's share price is determined by a range of factors such as market sentiment, financial performance, and general economic conditions.

Sun Pharma Advanced Research Company Ltd. Balance Sheet:

Analyzing Sun Pharma Advanced Research Company Ltd.'s balance sheet is fundamental to evaluating the company's overall financial health and growth potential. The balance sheet provides insights into the company's liquidity, debt levels, and current ratio. By utilizing our pre-built screening tools, investors can compare Sun Pharma Advanced Research Company Ltd.'s balance sheet with industry peers and evaluate potential investment opportunities for long-term growth.

Sun Pharma Advanced Research Company Ltd. Annual Report:

Sun Pharma Advanced Research Company Ltd.'s annual reports provide valuable information for long-term investors seeking a comprehensive understanding of the company's performance. Our website provides downloadable copies of Sun Pharma Advanced Research Company Ltd.'s annual reports, enabling investors to delve into the information provided and develop insights into potential investment opportunities. Additionally, we offer premium feature tools, such as DCF Analysis, BVPS Analysis, Earnings multiple approaches, and DuPont Analysis, which provide in-depth analysis for investors to make well-informed decisions about their long-term investment strategies.

Sun Pharma Advanced Research Company Ltd. Dividend:

For long-term stock investors seeking consistent returns, analyzing the dividend payout history of Sun Pharma Advanced Research Company Ltd. is essential. Assessing the consistency and growth potential of the company's dividend payouts is crucial. On our website, you can find information on Sun Pharma Advanced Research Company Ltd.'s dividend payouts, enabling analysis and comparison with industry peers. Our pre-built screening tools are designed to help investors identify potential investment opportunities and make informed decisions about their long-term investments.

Sun Pharma Advanced Research Company Ltd. Quarterly Results:

Analyzing Sun Pharma Advanced Research Company Ltd.'s quarterly results is critical for long-term investors seeking a comprehensive understanding of the company's performance over time. Our website offers quick access to detailed analysis of Sun Pharma Advanced Research Company Ltd.'s quarterly results, enabling investors to evaluate potential investment opportunities accurately. Additionally, we provide downloadable copies of Sun Pharma Advanced Research Company Ltd.'s quarterly reports on our website, allowing investors to perform in-depth analysis and gain valuable insights.

Sun Pharma Advanced Research Company Ltd. Stock Price:

Sun Pharma Advanced Research Company Ltd.'s stock price is a critical factor governing the company's long-term growth potential. Analyzing the trends in Sun Pharma Advanced Research Company Ltd.'s stock price over time and comparing its performance with industry peers is necessary for long-term investors seeking potential investment opportunities. Our website offers pre-built screening tools that enable quick analysis and identification of potential long-term investment opportunities, empowering investors to make well-informed decisions about their investment strategies. Our website provides pre-built screening tools to help investors analyze stock prices and performance.

Sun Pharma Advanced Research Company Ltd. Price Chart:

Graphical representation of Sun Pharma Advanced Research Company Ltd.'s stock price trends is highly beneficial for long-term investors seeking potential investment opportunities. By utilizing the price charts available on our website and combining them with our pre-built screening tools, investors can gain valuable insights into the company's performance and growth potential for long-term investments.

Sun Pharma Advanced Research Company Ltd. News:

Staying updated with the latest news and market developments is critical for long-term stock investors. Our website features timely articles and events related to Sun Pharma Advanced Research Company Ltd.'s stock market performance, enabling investors to stay up-to-date on the latest developments and make informed decisions about potential investment opportunities.

Sun Pharma Advanced Research Company Ltd. Concall Transcripts:

Analyzing Sun Pharma Advanced Research Company Ltd.'s con call transcripts provides long-term investors with critical insights into the company's future guidance, strategic initiatives, and financial performance. On our website, you can access Sun Pharma Advanced Research Company Ltd.'s con call transcripts as downloadable documents for in-depth analysis. Additionally, our premium feature tools, including DCF Analysis and Earnings multiple approaches, can help investors analyze the information provided in the transcripts and develop valuable insights for their long-term investment strategies.

Sun Pharma Advanced Research Company Ltd. Investor Presentations:

Sun Pharma Advanced Research Company Ltd.'s investor presentations offer a wealth of information for long-term investors interested in the company's growth potential. Our website provides downloadable copies of Sun Pharma Advanced Research Company Ltd.'s investor presentations, allowing investors to analyze detailed information and gain insights for long-term investment strategies. Utilizing our premium feature tools, such as BVPS Analysis and DuPont Analysis, investors can delve deeper into the information presented and make well-informed decisions.

Sun Pharma Advanced Research Company Ltd. Promoters and Shareholders:

Understanding the promoters and shareholders of Sun Pharma Advanced Research Company Ltd. is necessary for long-term investors. Our website provides detailed information about the company's promoters and shareholders, facilitating in-depth analysis and informed decision-making. By utilizing our pre-built screening tools, investors can analyze Sun Pharma Advanced Research Company Ltd.'s shareholding patterns and identify potential long-term growth opportunities.

Read More
X